Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — Investor Presentation (June 2025)
25 slides from Argent Biopharma's investor presentation, Jun 10, 2025
Slide 1: A drug discovery company dedicated to addressing unmet medical needs
For personal use only A drug discovery company dedicated to addressing unmet medical needs Focusing on the Central nervous system (CNS) June 2025 and Autoimmune systems Company Presentation
Slide 2: Disclaimer
Disclaimer The information contained in this presentation and any accompanying oral presentation (“Presentation”) is being document including representations or warranties or in relation to the accuracy or completeness of the information, supplied to you by Argent BioPharma on behalf of itself and i
Slide 3: Argent BioPharma is a specialized biopharmaceutical company
Argent BioPharma is a specialized Biopharmaceutical company focused For personal use only on developing and marketing innovative drugs. Committed to providing accessible medical treatments for unmet medical needs with Nano Neuro-Immune Modulation. Innovative Technology Platform: Utilizing advanced n
Slide 4: Vision and Mission
Vision Argent BioPharma aspires to become a biopharmaceutical company recognized For personal use only globally for its innovative treatments that address unmet medical needs, particularly in the central nervous system (CNS) and immune-related diseases. The company aims to be a key player in transfo
Slide 5: R&D Center and Manufacturing Capabilities
For personal use only R&D Center and Manufacturing Capabilities page 5
Slide 6: In house Research, Development & Production
In house Research, Development & Production For personal use only Wholly owned and Operated EU GMP Sites Slovenia R&D hub is staffed with highly experienced pharmaceutical industry professionals dedicated to developing advanced drug formulations and delivery systems. Slovenia Quality team, expertly
Slide 7: Slovenia – EU Research and Development site
Slovenia – EU Research and Development site For personal use only Integrated research hub ensuring innovation, patient access, long-term value, and a strong market position. Advanced R&D Operations: Operates with a team of skilled professionals, ensuring continuous innovation and progress in drug de
Slide 8: Malta – Manufacturing site
Malta – Manufacturing site For personal use only A fully built, modern EU GMP-certified Boutique manufacturing facility, operational for less than three years and supported by multi-million dollar grants from the Maltese government¹. Automated Production Capabilities: The facility features fully a
Slide 9: Key products
For personal use only Key products We utilize advanced nanotechnology and a multidisciplinary approach in our in-house R&D platform to develop innovative therapies for unmet medical needs. page 9
Slide 10: CannEpil® Refractory Epilepsy
CannEpil® Refractory Epilepsy Seizure Control Management For personal use only Early-Stage Revenue Generating Approximately 30% of generalized seizure epilepsy patients have Refractory Epilepsy, aka “Drug-Resistant Epilepsy" (DRE)¹, representing 15,000,000 patients around the world. CannEpil® is n
Slide 11: CannEpil® Market potential
CannEpil® Refractory Epilepsy Seizure Control Management For personal use only Early-Stage Revenue Generating Market potential Worldwide Potential Patients with DRE 15,000,000 USA Addressable Market 1,135,200 Germany Addressable Market 180,000 Key points CannEpil® already sold in the Germany, UK, Ir
Slide 12: CannEpil® Forward-looking
CannEpil® Refractory Epilepsy Seizure Control Management For personal use only Early-Stage Revenue Generating Forward-looking Commercial strategy is a combination of 3rd party distribution supported by in-house Medical Scientific Liaison. Continuing the work with the ‘I am Billy’ Foundation and the
Slide 13: CimetrA® Multi-target anti-inflammatory & immunomodulatory therapy
CimetrA® Multi-target anti-inflammatory & immunomodulatory therapy For personal use only Early-Stage Revenue Generating CimetrA®: a multi-target immunomodulator meeting critical unmet medical needs from acute ARDS to chronic autoimmune gaps (RA, IBD, lupus) where current therapies fall short. Cimetr
Slide 14: CimetrA® Immunomodulation Treatment for Acute lung injury and ARDS
CimetrA® Immunomodulation Treatment for Acute lung injury and ARDS For personal use only Early-Stage Revenue Generating Market potential Cases of severe illness of influenza worldwide 3 – 5M Respiratory deaths per annum 650,000 – 850,000 Key Points Sales strategy is to license and distribute through
Slide 15: CogniCann® Improving quality of life in Dementia and Alzheimer's
CogniCann® Improving quality of life in Dementia and Alzheimer’s For personal use only Early-Stage Revenue Generating 55 million people worldwide suffering from Dementia and Alzheimer’s¹ Approved in Germany under Special Access Scheme CogniCann® designed as a treatment for the symptoms associated wi
Slide 16: IrniCann®
IrniCann® Improving quality of life in Dementia and Alzheimer’s For personal use only Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease An
Slide 17: DerNaPol® Pre-Clinical Stage for Chronic Wounds Treatment
DerNaPol® Pre-Clinical Stage for Chronic Wounds Treatment For personal use only Chronic wounds are a major global health issue, costing billions in treatment annually (e.g., £3.2 billion in the UK¹ in 2015; $28.1 to $96.8 billion in the USA in 2014²). These wounds cause extreme suffering with severe
Slide 18: Research and Development Product Pipeline
Research and Development Product Pipeline US FDA & EMA Registration plan For personal use only Actively pursuing FDA approval with potential Orphan Drug Designation. European Medicines Agency (EMA) & the United States of America (USA) Food and Drug Administration (FDA) page 18
Slide 19: Qualified team
For personal use only Qualified team With versatile industry Experience and Expertise page 19
Slide 20: Roby Zomer and Igor Bluvstein
Roby Zomer Igor Bluvstein For personal use only Chief Executive Officer Chief Financial Officer Roby Zomer is an accomplished executive with extensive experience in the Igor is a seasoned Chief Financial Officer with extensive experience across biopharmaceutical and biotech industries. As the CEO of
Slide 21: Dr. Jonathan Grunfeld and Amir Polak
Dr. Jonathan Grunfeld Amir Polak For personal use only Vice president of Chief Pharmaceutical Medical Development Development Officer Dr. Jonathan Grunfeld is a highly experienced neurologist and neuro- Amir is a seasoned professional with over 18 years of experience in the oncologist with a career
Slide 22: Sabina Suljaković and Yair Tal
Sabina Suljaković Yair Tal For personal use only Chief Quality and Chief Information Security Commercial Officer Officer Sabina is an accomplished quality professional with over 10 years of With 30 years of extensive experience, Yair Tal specializes in providing experience, specializing in establish
Slide 23: Medical advisors
For personal use only Medical advisors page 23
Slide 24: Medical advisors
Dr. Shlomo Sadoun Prof. Uri Kramer Yossi Mograbi For personal use only Strategic Business Development Head of Neurology Strategic R/D Dr. Shlomo Sadoun has over 18 years of Professor Uri Kramer is a renowned neurologist, Mograbi is a seasoned biotech entrepreneur, experience in the pharmaceutical in
Slide 25: Addressing unmet medical needs
For personal use only Addressing unmet medical needs info@argentbiopharma.com @argentbiopharma @ArgentBioPharma Argent BioPharma Ltd. June 2025 Argent BioPharma Company Presentation